Purple Biotech (PPBT) Capital Expenditures (2015 - 2023)

Purple Biotech (PPBT) has reported Capital Expenditures for 8 consecutive years, with $1000.0 the latest figure, recorded in Q3 2023.

• On a quarterly basis, Capital Expenditures rose 116.67% year-over-year to $1000.0 in Q3 2023; TTM through Dec 2023 was -$3000.0, a 88.46% increase from a year earlier, with the FY2025 full-year figure at -$3000.0, changed N/A from the prior year.
• Capital Expenditures was $1000.0 for Q3 2023 at Purple Biotech, up from -$1000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $1000.0 in Q3 2023 and troughed at -$156000.0 in Q4 2020.
• A 5-year average of -$25750.0 and a median of -$6000.0 in 2021 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures plunged 5100.0% in 2020 and surged 116.67% in 2023, its largest moves.
• Over 5 years, Capital Expenditures stood at -$3000.0 in 2019, then sank by 5100.0% to -$156000.0 in 2020, then soared by 96.15% to -$6000.0 in 2021, then changed by 0.0% to -$6000.0 in 2022, then jumped by 116.67% to $1000.0 in 2023.
• The last three Capital Expenditures figures came in at $1000.0 (Q3 2023), -$1000.0 (Q2 2023), and -$3000.0 (Q1 2023), per Business Quant data.